文献速递泌尿男性生殖肿瘤

厄达替尼用于卡介苗治疗后的高危非肌层浸润性膀胱癌

Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer.
PubMed 文献 · Ann Oncol · 2023-10-21

这项随机试验纳入卡介苗治疗后复发、拒绝或不适合根治性膀胱切除术、携带特定FGFR3/2改变的高危非肌层浸润性膀胱癌患者,比较口服厄达替尼与膀胱内化疗。研究因入组缓慢提前终止,共随机73例(厄达替尼49例、化疗24例)。厄达替尼组中位无复发生存期未达到,化疗组为11.6个月,估计风险比为0.28。

要点

  • 厄达替尼组中位无复发生存期未达到,化疗组为11.6个月,估计HR为0.28。
  • 研究因入组缓慢提前终止,厄达替尼组49例、化疗组24例。
  • 安全性结果与厄达替尼和化疗已知特征总体一致。

核心结论

  • 在卡介苗治疗后复发、拒绝或不适合根治性膀胱切除术、携带FGFR改变的纯乳头状高危非肌层浸润性膀胱癌患者中,厄达替尼较膀胱内化疗延长了无复发生存期。

研究设计与样本

  • 随机对照试验:患者按2:1随机分配至每日口服厄达替尼6 mg组(n=49)或研究者选择的膀胱内化疗组(丝裂霉素C或吉西他滨,n=24)。
  • 纳入年龄≥18岁、卡介苗治疗后复发、纯乳头状高危非肌层浸润性膀胱癌(高级别Ta/T1)、携带特定FGFR改变且拒绝或不适合根治性膀胱切除术的患者。
  • 主要终点为无复发生存期,关键次要终点为安全性。
  • 研究因入组缓慢而停止入组,共随机73例患者。

主要发现

  • 厄达替尼组中位无复发生存期未达到(95%CI 16.9个月至不可估计),化疗组为11.6个月(95%CI 6.4至20.1个月)。
  • 估计风险比为0.28(95%CI 0.1至0.6;名义P值=0.0008)。
  • 两组无复发生存期的中位随访时间均为13.4个月。
  • 在该人群中,安全性结果与厄达替尼和化疗的已知特征总体一致。

局限性

  • 研究因入组缓慢而停止入组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment options are limited for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) with disease recurrence after bacillus Calmette-Guérin (BCG) treatment and who are ineligible for/refuse radical cystectomy. FGFR alterations are commonly detected in NMIBC. We evaluated the activity of oral erdafitinib, a selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, versus intravesical chemotherapy in patients with high-risk NMIBC and select FGFR3/2 alterations following recurrence after BCG treatment. PATIENTS AND METHODS: Patients aged ≥18 years with recurrent, BCG-treated, papillary-only high-risk NMIBC (high-grade Ta/T1) and select FGFR alterations refusing or ineligible for radical cystectomy were randomized to 6 mg daily oral erdafitinib or investigator's choice of intravesical chemotherapy (mitomycin C or gemcitabine). The primary endpoint was recurrence-free survival (RFS). The key secondary endpoint was safety. RESULTS: Study enrollment was discontinued due to slow accrual. Seventy-three patients were randomized 2 : 1 to erdafitinib (n = 49) and chemotherapy (n = 24). Median follow-up for RFS was 13.4 months for both groups. Median RFS was not reached for erdafitinib [95% confidence interval (CI) 16.9 months-not estimable] and was 11.6 months (95% CI 6.4-20.1 months) for chemotherapy, with an estimated hazard ratio of 0.28 (95% CI 0.1-0.6; nominal P value = 0.0008). In this population, safety results were generally consistent with known profiles for erdafitinib and chemotherapy. CONCLUSIONS: Erdafitinib prolonged RFS compared with intravesical chemotherapy in patients with papillary-only, high-risk NMIBC harboring FGFR alterations who had disease recurrence after BCG therapy and refused or were ineligible for radical cystectomy.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Catto JWF, Tran B, Rouprêt M, et al. Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer. Ann Oncol. 2023. PMID: 37871701. doi:10.1016/j.annonc.2023.09.3116

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。